Samyang Biopharmaceuticals Corporation of Seongnam-si, Gyeonggi-do at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Samyang Biopharmaceuticals Corporation

295 Pangyo-ro, Bundang-gu, 13488 Seongnam-si, Gyeonggi-do
Korea, Republic
Telephone +82 2 2157 9833
Fax +82 2 2157 9062

Hall map

MEDICA 2019 hall map (Hall 5): stand L11

Fairground map

MEDICA 2019 fairground map: Hall 5


Hongsik Kim

+82 2 2157 9833


Our range of products

Product categories

  • 05  Commodities and Consumer Goods
  • 05.07  Disposables
  • 05.07.03  Disposable articles for surgeries

Our products

Product category: Disposable articles for surgeries

Synthetic Suture Material (Bulk Thread)

- Absorbable Multifilament : TRISORB(PGA), TRISORB Rapid, NEOSORB(PGLA), NEOSORB Rapid

- Absorbable Monofilament : MONOSORB(PDO), MONOFAST(PGCL)

- Antibacterial Sutures : TRISORB Plus(PGA), NEOSORB Plus (PGLA), MONOSORB Plus (PDO), MONOFAST Plus (PGCL)

More Less

Product category: Disposable articles for surgeries


- Oxidized Regenerated Cellulose (ORC) Hemostat
- Absorbable knitted fabric composed by ORC (Oxidized Regenerated Cellulose)
- Surgical Procedures to assist in the control of capillary, venous, and small arterial hemorhage

More Less

Product category: Disposable articles for surgeries

Barbed Suture

- Absorbable barbed suture(PDO, PGCL)

- Knotless barbed suture

- 3 Features: premium quality needle, stopper security, barbing pattern security

More Less

About us

Company details

Samyang Biopharmaceuticals Corp. is a pharmaceutical company that was established in 2011 following the separation of the pharmaceutical business of Samyang.

Samyang Biopharmaceuticals Corp.'s pharmaceutical business is one of the three major growth drivers of the Samyang Group, along with the chemical and food businesses. Since its entry into the pharmaceutical business in 1995, Samyang Biopharmaceuticals Corp. has invested more than 20% of its annual sales in its pursuit of innovative R&D.

In doing so, we are engaged in new medical technology and pharmaceuticals, such as the drug delivery system (DDS), and are currently developing and conducting sales of anticancer drugs, Genexol® and Nanoxel® M, a smoking cessation patch, Nicostop®, and biodegradable surgical sutures, Trisorb® and Monosorb®.

In particular, Genexol® PM and Nanoxel® PM, which are anticancer drugs, continue to display excellent efficacy, such as the reduction of side effects by applying our own drug delivery technology (DDS). Also, our biodegradable surgical sutures are the third most successful medical device we produce and are exported to more than 150 customers in 45 countries around the world.

In April 2016, we completed construction of the Samyang Discovery Center in Pangyo Techno Valley, which has advanced R&D facilities. This center, viewed as a R&D mecca for Samyang Biopharmaceuticals Corp. will serve as the foundation for us to be defined as a global pharmaceutical company.

Moreover, Samyang Biopharmaceuticals Corp. has already been recognized as an innovative pharmaceutical company by the Ministry of Health and Welfare in 2012 based on our strong investment in R&D and technological prowess.

Samyang Biopharm will continuously develop pharmaceuticals and medical devices that will enhance human health and enrich the quality of life, and thereby secure the undoubted trust our customers, creating new values, facing the challenges of creating new values and innovation, nurturing talents, and furthermore, growing and progressing as a global pharmaceutical company.

We established Samyang Biopharm USA Inc. in Cambridge, MA in October 2018, and are expanding into immuno-oncology drugs and rare-diseases drugs market in the U.S

More Less